Tg therapeutics, inc. (TGTX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Sep'11Jun'11Sep'10Jun'10
License revenue

152

152

152

152

152

152

152

152

152

152

151

151

151

152

152

152

152

152

152

152

152

152

152

152

152

152

133

95

57

19

0

0

0

-

-

-

-

Costs and expenses:
Research and development:
Non cash stock expense associated with in-licensing agreements

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

0

16,578

16,578

16,875

0

0

0

-

-

Noncash compensation

0

-

-

-

0

-

-

-

-

5,647

3,174

4,093

4,661

2,742

3,402

2,518

3,310

4,261

5,062

6,227

8,167

8,731

6,551

5,522

2,588

1,041

1,111

1,067

810

455

236

0

0

0

-

-

-

Noncash compensation

-

-

0

0

-

-

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other research and development

151,416

148,269

169,881

146,132

148,530

149,793

124,460

117,041

108,669

96,886

92,565

88,109

75,635

66,490

58,801

49,461

46,396

43,445

42,527

39,341

31,775

26,004

16,803

11,589

13,914

12,621

9,874

8,170

5,046

3,994

3,149

1,716

0

0

0

-

-

In-process research and development charge

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Loss on disposition of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Total research and development

157,817

154,180

175,511

150,924

156,758

159,391

133,112

126,863

114,869

102,533

98,820

93,468

80,296

69,232

62,203

51,979

49,707

47,707

47,589

49,707

45,293

40,086

28,705

18,323

16,502

13,662

10,986

9,238

5,856

21,027

19,964

18,700

0

0

0

0

0

General and administrative:
Noncash compensation

14,219

5,523

1,643

233

3,203

7,288

10,346

14,239

11,087

10,298

7,447

6,285

7,143

4,767

5,636

4,926

8,728

11,435

12,816

14,507

14,063

12,373

10,462

8,391

4,960

4,161

4,387

4,253

4,308

2,966

1,942

1,251

0

0

0

-

-

Other general and administrative

12,727

9,504

8,242

7,706

7,703

7,873

7,980

7,593

6,819

6,033

5,588

5,441

5,354

5,122

4,893

4,727

4,285

4,189

4,007

3,812

3,514

3,413

3,162

2,823

2,748

2,496

2,334

2,246

2,011

1,815

1,328

865

0

0

0

-

-

Total general and administrative

26,946

15,027

9,885

7,939

10,906

15,161

18,326

21,832

17,906

16,331

13,035

11,727

12,498

9,889

10,530

9,654

13,014

15,625

16,823

18,319

17,577

15,787

13,625

11,215

7,709

6,658

6,722

6,500

6,319

4,781

3,270

2,117

0

0

0

0

0

Impairment of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,104

1,104

0

0

0

-

-

-

-

Total costs and expenses

184,763

169,207

185,396

158,863

167,664

174,552

151,438

148,695

132,775

118,864

111,855

105,196

92,794

79,121

72,733

61,633

62,721

63,332

64,413

68,027

62,871

55,873

45,128

32,336

27,009

23,118

18,814

16,842

13,280

26,914

23,234

20,817

0

0

0

-

-

Operating loss

-184,611

-169,055

-202,846

-176,313

-167,512

-174,400

-62,596

-59,853

-132,623

-118,712

-111,703

-105,044

-92,642

-78,969

-72,581

-61,481

-62,569

-63,180

-64,261

-67,874

-62,718

-55,721

-44,975

-32,183

-26,857

-22,965

-18,680

-16,747

-13,223

-26,895

-23,234

-20,817

0

0

0

0

0

Other (income) expense:
Equity in losses of Hedrin JV

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Gain on Nordic Settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Interest and other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Interest expense

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

936

942

947

952

940

928

917

905

676

448

0

0

0

0

0

Interest expense

-

-

-

1,716

-

-

-

567

394

-

231

240

283

323

330

298

237

174

126

82

63

55

54

54

42

30

0

0

0

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15

12

7

0

0

0

-

-

Other income

1,494

1,471

2,050

2,180

2,198

1,795

2,123

1,495

1,091

1,081

182

218

228

393

96

0

0

-

0

-

-

-115

204

204

204

108

0

0

272

272

272

272

0

0

0

-

-

Change in fair value of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

3,005

3,113

3,205

3,300

1,617

1,525

1,724

1,659

915

687

0

0

0

-

-

Total other expense (income), net

-4,220

-3,816

2,315

869

403

918

50

476

345

236

413

459

511

716

390

465

349

231

127

-53

-92

-60

2,327

2,430

2,505

2,487

694

607

1,093

1,042

523

519

0

0

0

0

0

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-12,130

-25,852

0

0

0

-

-

-

-

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

330

330

0

0

0

-

-

-

-

Net loss

-188,831

-172,871

-203,017

-175,038

-167,109

-173,482

-62,198

-59,783

-132,278

-118,476

-111,290

-104,585

-92,131

-78,253

-72,190

-61,015

-62,219

-62,948

-64,133

-67,928

-62,811

-55,781

-42,648

-29,753

-24,351

-20,478

-18,316

-16,470

-12,460

-26,182

-22,711

-20,297

0

0

0

-

-

Net loss attributable to non-controlling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-969

-8,110

-8,069

-7,836

0

0

0

-

-

Loss on early extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Realized gain on sale of marketable equity securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss attributable to TG Therapeutics, Inc. and Subsidiaries

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,490

-18,072

-14,641

-12,461

0

0

0

0

0

Preferred stock dividends (including imputed amounts)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net income (loss) applicable to common shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Basic and diluted net loss per common share (in dollars per share)

-0.48

-1.26

-0.69

0.42

-0.43

-1.87

-0.43

0.59

-0.59

-0.46

-0.48

-0.45

-0.52

-0.49

-0.50

-0.33

-0.28

-0.37

-0.28

-0.38

-0.35

-0.52

-0.51

-0.36

-0.25

-0.19

-0.16

-0.29

-0.17

0.97

-0.16

-0.16

-2.03

-0.01

-0.15

0.02

0.77

Weighted average shares used in computing basic and diluted net loss per common share (in shares)

105,461

95,833

89,667

86,800

81,174

78,752

78,221

74,256

70,636

66,753

65,079

63,288

53,157

49,283

49,203

48,769

48,908

48,229

47,946

45,320

41,088

39,011

34,188

32,985

30,091

29,533

27,684

22,483

21,953

19,805

15,810

11,777

5,061

2,632

1,822

2,419

2,408